Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator.

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Eun-Jeong KimRoy M John

Abstract

Cardiac amyloidosis (CA) is associated with increased mortality due to arrhythmias, heart failure, and electromechanical dissociation. However, the role of an implantable cardioverter-defibrillator (ICD) remains unclear. We conducted case-control study to assess survival in CA patients with and without a primary prevention ICD and compared outcomes to an age, sex, and device implant year-matched non-CA group with primary prevention ICD. There were 91 subjects with CA [mean age= 71.2 ± 10.2, female 22.0%, 49 AL with Mayo Stage 2.9 ± 1.0, 41 transthyretin amyloidosis (ATTR), 1 other] followed by Vanderbilt Amyloidosis centre. Patients with ICD (n = 23) were compared with those without (n = 68) and a non-amyloid group with ICD (n = 46). All subjects with ICD had implantation for primary prevention. Mean left ventricular ejection fraction was 36.2% ± 14.4% in CA with ICD, 41.0% ± 10.6% in CA without ICD, and 33.5% ± 14.4% in non-CA patients. Over 3.5 ± 3.1 years, 6 (26.1%) CA, and 12 (26.1%) non-CA subjects received ICD therapies (P = 0.71). Patients with CA had a significantly higher mortality (43.9% vs. 17.4%, P = 0.002) compared with the non-CA group. Mean time from device implantation to death was 21.8 months in AL and 22.8 mon...Continue Reading

References

Oct 1, 1985·Journal of the American College of Cardiology·L Cueto-GarciaA J Tajik
May 14, 1998·QJM : Monthly Journal of the Association of Physicians·S W DubreyR H Falk
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela DispenzieriAllan S Jaffe
Jan 5, 2005·Circulation·Alicia Maria MaceiraDudley John Pennell
Feb 5, 2008·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Arnt V KristenAlexander Bauer
Sep 6, 2012·Circulation·Frederick L Ruberg, John L Berk
Mar 16, 2013·Journal of Cardiovascular Electrophysiology·Grace LinPeter A Brady
Apr 24, 2013·Journal of the American Heart Association·Jennifer H PinneyHelen J Lachmann
Oct 15, 2013·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Brandon C VarrRonald M Witteles
Aug 19, 2016·Kidney Diseases·Hans L A NienhuisBouke P C Hazenberg
Mar 11, 2017·Heart Failure Reviews·Matthew SousaMaya Guglin
Apr 25, 2017·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Camille V EdwardsSuzanne Lentzsch
Aug 28, 2018·The New England Journal of Medicine·Mathew S MaurerUNKNOWN ATTR-ACT Study Investigators
May 13, 2019·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Jeffrey A TowbinWojciech Zareba

❮ Previous
Next ❯

Citations

Mar 17, 2021·Current Oncology Reports·Lily K Stern, Michelle M Kittleson
Sep 3, 2021·Heart Failure Reviews·Morris M KimAhmad Masri
Nov 5, 2021·ESC Heart Failure·Kilian FischerCharles Guenancia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.

Related Papers

Journal of Cardiovascular Electrophysiology
Grace LinPeter A Brady
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Takekuni HayashiHarumizu Sakurada
JAAPA : Official Journal of the American Academy of Physician Assistants
Mary L Hewett
South Dakota Medicine : the Journal of the South Dakota State Medical Association
Daniel J Heinemann
© 2022 Meta ULC. All rights reserved